Sertraline Dosing Recommendations
Start sertraline at 50 mg once daily for adults with depression, 25 mg daily for adolescents (ages 13-17) and children (ages 6-12), with lower or less frequent dosing (50 mg or less) required for elderly patients and those with hepatic impairment.
Adult Dosing (Depression, OCD, Panic Disorder)
Standard Adult Dosing
- Starting dose: 50 mg once daily 11
- Therapeutic dose: 50 mg/day is the optimal dose for most patients considering both efficacy and tolerability 2
- Titration: If inadequate response after 2-4 weeks, increase in 50 mg increments at weekly intervals 2
- Maximum dose: 200 mg/day 11
- Timing: Can be administered any time of day, morning or evening 1
The FDA label confirms that in clinical trials, mean doses for completers ranged from 70-186 mg/day depending on indication, though 50 mg often suffices 11. A 2023 dose-response meta-analysis found therapeutic response increases with dosage, but adverse effects also increase above 150 mg 3.
Elderly Patients (≥60 years)
- Dosing adjustment: Lower or less frequent dosing recommended 1
- Rationale: Sertraline clearance is approximately 40% lower in elderly patients, with prolonged elimination half-life 1
- Preferred agent: Sertraline is specifically recommended for elderly patients with depression due to favorable tolerability profile 45
- No strict age-based reduction needed: Despite pharmacokinetic differences, some sources indicate no mandatory dose reduction solely based on age 25
Clinical approach: Start at 50 mg daily but monitor closely; consider 25 mg starting dose in frail elderly or those on multiple medications.
Hepatic Impairment
- Mandatory dose reduction: Lower or less frequent dosing required 1
- Pharmacokinetic basis: In mild hepatic impairment (Child-Pugh 5-8), sertraline clearance is reduced, resulting in approximately 3-fold greater drug exposure 16
- Specific recommendation: Maximum 50 mg daily or consider alternate-day dosing in moderate-to-severe impairment
- Caution: Effects in moderate-to-severe hepatic impairment have not been formally studied 1
A 1996 study confirmed 1.7-fold increase in peak concentration and prolonged elimination half-life in cirrhotic patients 6.
Renal Impairment
- No adjustment needed: Sertraline pharmacokinetics are unaffected by renal impairment, including patients on hemodialysis 11
Pediatric/Adolescent Dosing (OCD, Depression)
Adolescents (Ages 13-17)
- Starting dose: 50 mg once daily 7
- Titration: Increase by 50 mg increments weekly as needed 7
- Effective dose: 50 mg/day 7
- Maximum dose: 200 mg/day 7
Children (Ages 6-12)
- Starting dose: 25 mg once daily 78
- Titration: Increase by 25 mg increments weekly as needed 7
- Effective dose: 50 mg/day (weight-adjusted) 7
- Maximum dose: 200 mg/day 7
Important caveat: Only fluoxetine is FDA-approved for pediatric depression; escitalopram is approved for adolescents ≥12 years. Sertraline is FDA-approved only for pediatric OCD 71. The GLAD-PC guidelines note that effective dosages in adolescents are generally lower than adult guidelines 7.
Pediatric Pharmacokinetic Considerations
- Pediatric patients (ages 6-17) show approximately 22% lower drug exposure when adjusted for weight compared to adults 1
- Mean sertraline AUC in children (6-12 years): 3107 ng-hr/mL vs. adults: 2570 ng-hr/mL (higher due to lower body weight) 1
- Clinical implication: Lower doses may be advisable, especially in very young patients, to avoid excessive plasma levels 1
Monitoring in Pediatric Patients
- Weight monitoring essential: Approximately 7% of children experienced >7% body weight loss in trials (vs. 0% placebo) 1
- Close follow-up required: Contact within first week after initiation to assess adherence, adverse effects, and suicidality 7
- Black box warning: Monitor closely for clinical worsening, suicidality, and unusual behavioral changes, especially during initial months and dose changes 71
Key Clinical Pearls
Steady-State Timing
- Adults: 1 week at constant dose 1
- Elderly: 2-3 weeks due to reduced clearance 1
- Adequate trial duration: Maintain maximum tolerated dose for sufficient duration before declaring treatment failure
Discontinuation
- Always taper slowly to avoid withdrawal effects 7
- Never abruptly discontinue
Drug Interactions
- Contraindicated with MAOIs 7
- Low potential for cytochrome P450 interactions compared to other SSRIs 5
- Caution with other serotonergic agents (risk of serotonin syndrome) 4